Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors-Reference-Cited by-同舟云学术

Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors

Published:2021-04-19 Issue:9 Volume:64 Page:5787-5801
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Muthengi Alex¹,Wimalasena Virangika K.²,Yosief Hailemichael O.¹,Bikowitz Melissa J.³⁴^ORCID,Sigua Logan H.²,Wang Tingjian²,Li Deyao²,Gaieb Zied⁵,Dhawan Gagan⁶^ORCID,Liu Shuai¹,Erickson Jon¹,Amaro Rommie E.⁵^ORCID,Schönbrunn Ernst³⁴^ORCID,Qi Jun²⁷,Zhang Wei¹^ORCID

Affiliation:

1. Center for Green Chemistry and Department of Chemistry, University of Massachusetts Boston, 100 Morrissey Boulevard, Boston, Massachusetts 02125, United States

2. Department of Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, United States

3. Drug Discovery Department, Moffit Cancer Center, Tampa, Florida 33612, United States

4. Department of Molecular Medicine, USF Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States

5. Department of Chemistry & Biochemistry, University of California, San Diego, 9500 Gilman Dr, LA Jolla, California 92093, United States

6. Department of Biomedical Science, Acharya Narendra Dev College, University of Delhi, Delhi, New Delhi 110019, India

7. Department of Medicine, Harvard Medical School, 220 Longwood Avenue, Boston, Massachusetts 02115, United States

Funder

National Cancer Institute

Alex's Lemonade Stand Foundation for Childhood Cancer

National Institute of Mental Health

National Institutes of Health

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c02232

Reference42 articles.

1. Advancements in the Development of non‐BET Bromodomain Chemical Probes

2. Clinical progress and pharmacology of small molecule bromodomain inhibitors

3. Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions

4. Targeting bromodomains: epigenetic readers of lysine acetylation

5. The Bromodomain: A New Target in Emerging Epigenetic Medicine

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of an EP300 Inhibitor using Structure-based Virtual Screening andBioactivity Evaluation;Current Pharmaceutical Design;2024-07

2. Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatment;Pharmacology & Therapeutics;2024-05

3. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition;Nature Communications;2024-04-25

4. Microwave Assisted Groebke-Blackburn-Bienayme Multicomponent Reaction to Synthesis of Imidazo[1,2-a]pyridine-furan Hybrids as Possible Therapeutic Option for Leukemia, Colon Cancer and Prostate Cancer;Current Microwave Chemistry;2024-04

5. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia;Bioorganic Chemistry;2024-01